Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $395
Argus Research Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $375
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $420
Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $432
United Therapeutics Analyst Ratings
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $425
Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $395
BofA Securities Maintains United Therapeutics(UTHR.US) With Sell Rating, Raises Target Price to $328
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $400
UBS Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $460
Morgan Stanley Maintains United Therapeutics(UTHR.US) With Hold Rating, Raises Target Price to $354
BofA Adjusts Price Target on United Therapeutics to $328 From $327
United Therapeutics Analyst Ratings
UBS Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $475
Argus Research Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Is Maintained at Buy by Argus Research
Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $432
United Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $425
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $395 to $600